Teva launches generic of Syprine
Teva has introduced its generic Syprine (trientine hydrochloride) capsules. The drug was included on the Food and Drug Administration’s list of off-patent, off-exclusivity branded drugs that didn’t have generics.
“Teva filed our [abbreviated new drug application] more than two years ago and we are pleased that the FDA has now approved our applications and we are able to offer a lower-cost generic alternative to patients,” Teva executive vice president of global R&D Hafrun Fridriksdottir said. “We look forward to working closely with the FDA on their review of our many other generic applications.”
The drug is indicated to treat patients with Wilson’s disease — a genetic disorder that prevents the body from removing excess copper — who are intolerant of penicillamine. Teva’s generic Syprine will be available in 250-mg dosage strength.
Wilson’s disease is estimated to affect roughly 1-in-30,000 individuals. The drug had U.S. sales of roughly $155 million for the 12 months ended November 2018, according to IQVIA data.
“The launch of trientine hydrochloride capsules illustrates Teva’s commitment to serving patient populations in need—whether it’s a medicine that could be taken by millions of individuals or one focused on a rare condition disorder like Wilson’s disease,” Teava executive vice president and head of North America commercial Brendan O’Grady said.
Upsher-Smith, NASPA honor 45 pharmacists
Upsher-Smith Labs and the National Alliance of State Pharmacy Associations have announced the recipients of the 2017 NASPA Excellence in Innovation award.
The award, sponsored by the Maple Grove, Minn.-based manufacturer and coordinated by NASPA, recognized 45 pharmacists for their contributions to the pharmacy profession. The pharmacists received the award from their state pharmacy associations over the course of 2017.
“Upsher-Smith is proud to be a continued sponsor of NASPA’s Excellence in Innovation Award,” Upsher-Smith president and CEO Rusty Field said. “We are honored to give recognition to these awardees that have demonstrated innovation in the pharmacy profession and advanced patient care. Upsher-Smith shares these values and understands the critical role pharmacy plays in improving the health and lives of patients.”
The award is meant to recognize pharmacists who have shown significant innovation in their practice, method or service that results in improved patient care or advancing the profession of pharmacy.
“We appreciate Upsher-Smith for supporting the Excellence in Innovation Award,” NASPA executive vice president and CEO Rebecca Snead said. “The pharmacists honored have demonstrated exemplary professional achievements and innovation. We are proud to partner with Upsher-Smith and recognize these leaders for their commitment to advancing the pharmacy profession and improving the lives of patients across America every day.”
The pharmacists recognized were:
- Alabama: Patrick Devereux;
- Alaska: Karen Thompson;
- Arizona: Alyssa M. Peckham;
- Arkansas: Jody Smotherman;
- California: Christine Givant;
- Colorado: Paul B. Shaw;
- Connecticut: Ellen Jones;
- Delaware: Stephanie Pro;
- Florida: Damien D. Simmons;
- Georgia: Jennifer Shannon;
- Illinois: Starlin Haydon-Greatting;
- Indiana: Carrie Morton;
- Iowa: Jordan Schultz;
- Kansas: Molly Aldrich;
- Kentucky: Melanie Dicks, Holly Divine and Tera McIntosh;
- Louisiana: Jennifer Boudreaux;
- Maine: Courtney Doherty Oland;
- Maryland: Neil Leikach and Dixie Leikach;
- Massachusetts: Allison E. Burns;
- Michigan: Andrew J. Reeves;
- Minnesota: Anjoli Punjabi;
- Mississippi: Amanda Wilburn;
- Missouri: Stuart D. Federman;
- Montana: Michael F. Bertagnolli;
- New Hampshire: Eric R. Lessard;
- New Jersey: Domenic DiPrimo;
- New Mexico: Brian Hunt;
- New York: Christopher Daly;
- North Carolina: Robert F. Carta;
- North Dakota: Briana D. Fluhrer;
- Ohio: Erin L. Thompson;
- Oklahoma: Travis B. Wolff;
- Pennsylvania: Melissa Somma McGivney;
- Rhode Island: Linda Rowe-Varone;
- South Carolina: Deborah D. Bowers;
- Tennessee: Philip J. Baker;
- Virginia: Tana Kaefer;
- Washington: Monica Graybeal;
- Washington; DC: Carlisha Gentles;
- West Virginia: Jason Turner;
- Wisconsin: Erica Guetzlaff; and
- Wyoming: Shawn Dalton.
Lupin intros Tamiflu generic
Lupin has launched its generic of Tamiflu (oseltamivir) capsules. The drug is indicated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older who’ve shown symptoms for no more than 48 hours. It also is indicated to prevent the flu in patients age 1 year and older.
Lupin’s generic will be available in 30-, 45- and 75-mg (base) dosage strengths. The product had U.S. sales of roughly $518 million for the 12 months ended December 2017, according to IQVIA data.